PedialyDx Inc. was formed to commercialize technology derived from research at Brown University and Women & Infants Hospital that has demonstrated that the acoustics of an infant’s cry can indicate the immediate and long-term developmental outcome of the baby.
CEO
Pete ONeill was the founding CEO for the company Custom Orthopaedic Solutions (COS), which developed patient-specific surgical planning software and instrumentation for the orthopedic and pulmonology fields. The primary product for COS was OrthoVis, a system that consisted of a web portal and desktop software. The system allowed surgeons to upload CT scans for their patients through the company web portal. OrthoVis was cleared as FDA Class 2 through the 510(k) process. At a high level the NOWS-App we will develop will have a similar workflow to that OrthoVis system. Previously, Mr. ONeill was Executive Director of Cleveland Clinic Innovations, and Deputy Director of the Great Lakes Industrial Technology Center.
VP Clinical Operations
Chip has 30+ years of experience guiding the design, development and validation of clinical devices and applications that improve patient care. In the field of clinical biometrics he has assisted in the validation of neuromodulatory treatment technologies that alleviate pain and motor disabilities. In addition, Chip helped to validate the role of eye gaze as a biomarker for neurodevelopmental disorders such as autism spectrum and attention deficit disorders. Additionally Chip developed a Minimally Invasive Surgery Center of Excellence at a large academic medical center, a strategic partnership between surgeons, biomedical engineers and technology providers, which pioneered tele-surgery, tele-mentoring and tele-robotics to improve clinical outcomes and drive operational efficiencies. Later Chip led a multidisciplinary group of clinical leaders, software engineers and business executives to develop an AI system to better deliver the right treatment for the right patient at the right time resulting in better clinical outcomes at lower cost.
VP Product Development
Brian Beckrest is a software engineer with extensive experience in the design and development of HIPAA-compliant web applications. He has been responsible for end-to-end ownership of deliveries to production for the Arthrex Virtual Implant Positioning (VIP) and VisionAir 3D Stent Architect systems, both FDA 510(k)-cleared software systems. Throughout the development of these systems, he has placed a great emphasis on using software engineering best practices, enforcing them via automated tooling such as linters and code formatters, as well as adhering to test-driven development (TDD) to minimize bugs and improve code quality. This approach continues to be valuable as translated to the development of the NOWS-App.
Advisor
Barry M. Lester, Ph.D. is Professor of Psychiatry & Human Behavior and Pediatrics and Director of the Brown Center for the Study of Children at Risk at the Brown Alpert Medical School and Women & Infants Hospital. The Brown Center also includes the Center for Children and Families at Women & Infants Hospital. The Centers provide research and clinical services for infants at risk and their families as well as research and clinical training. Dr. Lester's research has been federally funded throughout his career. He has been heavily involved in the NIH peer review process serving on NIH study sections, the NIH National Advisory Council on Drug Abuse, the NIH Director's Pioneer Award Program and the College of the Center for Scientific Review. He is past president of the International Association for Infant Mental Health and the author of more than 250 peer reviewed publications and 100 chapters and books.
Advisor
Dr. Sheinkopf’s research employs novel approaches to studying risk for autism in infancy and on improved understanding of heterogeneous outcomes in autism spectrum disorders. Current projects utilize psychophysiology tools to interrogate individual differences in attention, arousal, and regulation in relation to developmental outcomes in children and adults with autism, and use of cry acoustics and neurobehavioral measures to identify indicators of risk for autism in early infancy. Dr. Sheinkopf’s research extends to other pediatric populations as well, including research on developmental course in children with prenatal exposures and children born premature. Throughout his career, Dr. Sheinkopf has maintained a deep commitment to clinical service, training, and mentorship. He maintains an active early diagnostic clinic and has mentored numerous trainees, ranging from undergraduate students to early career clinicians and scientists.
Get in touch with us to learn more about the work we are doing, inquire about upcoming studies, or discuss potential investment opportunities.
